Skip to main content
. 2017 Apr 26;114(19):4993–4998. doi: 10.1073/pnas.1705327114

Fig. S7.

Fig. S7.

Minimal effects of PD-1–targeted therapies on EBV-specific PD-1+ CD8 T cells. (A, Left) Dot plots show PD-1 and EBV-TET staining on CD8 T cells. (A, Right) Dot plots show proliferation of PD-1+ EBV-TET+ CD8 T cells and PD-1+ EBV-TETneg CD8 T cells at baseline (pre) and at the best CD8 T-cell response posttreatment (post). Data from NSCLC patient 2. (B) Dot plots show EBV-TET staining on CD8 T cells at baseline (pre) and at the best CD8 T-cell response posttreatment (post). (C) As in B, but dot plots show CD38 and HLA-DR expression on EBV-specific CD8 T cells (blue dots) over the gray contour plot for total CD8 T cells. Numbers inside dot plots indicate the percentage of EBV-specific CD8 T cells that coexpress HLA-DR and CD38. (D) Dot plots show PD-1 expression on EBV-specific and total CD8 T cells at baseline. Data in B–D is from whole blood of three patients as indicated.